# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

I Background Information:

A 510(k) Number K231316   
B Applicant Hologic, Inc.   
C Proprietary and Established Names Aptima Trichomonas vaginalis Assay   
D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>OUY</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 866.3860 -Trichomonas VaginalisNucleic Acid Assay</td><td rowspan=1 colspan=1>MI - Microbiology</td></tr></table>

# II Submission/Device Overview:

# A Purpose for Submission:

The Aptima Trichomonas vaginalis assay on the Panther System was previously cleared under K122062 for use with the following specimens from symptomatic or asymptomatic individuals: clinician-collected endocervical swabs, clinician-collected vaginal swabs, and specimens collected in PreservCyt Solution. Clearance of this pre-market submission adds patient-collected vaginal swab, and male and female urine from symptomatic and asymptomatic individuals as additional acceptable specimen types for use with the Aptima Trichomonas vaginalis (TV) assay on the Panther system.

# B Measurand:

Trichomonas vaginalis ribosomal RNA

# C Type of Test:

Automated, nucleic acid amplification test (NAAT) for qualitative detection of ribosomal RNA (rRNA). The Aptima Trichomonas vaginalis assay involves the technologies of target capture, transcription-mediated amplification (TMA), and hybridization protection assay (HPA).

# III Intended Use/Indications for Use:

# A Intended Use(s):

The Aptima Trichomonas vaginalis (TV) assay is an in vitro qualitative nucleic acid amplification test (NAAT) for the detection of ribosomal RNA (rRNA) from Trichomonas vaginalis to aid in the diagnosis of trichomoniasis using the Panther System.

The assay may be used to test the following specimens from symptomatic or asymptomatic individuals: clinician-collected endocervical swabs, clinician-collected and patient-collected vaginal swabs (in a clinical setting), female and male urine, and specimens collected in PreservCyt Solution.

B Indication(s) for Use: Same as Intended Use   
C Special Conditions for Use Statement(s): Rx - For Prescription Use Only   
D Special Instrument Requirements: PANTHER System automated analyzer

# IV Device/System Characteristics:

# A Device Description:

The Aptima Trichomonas vaginalis (Aptima TV) assay is a nucleic acid amplification test, intended for the in vitro qualitative detection of ribosomal RNA from Trichomonas vaginalis (TV) in clinician-collected and patient-collected vaginal swabs, clinician-collected endocervical swabs, male and female urine, and specimens collected in PreservCyt solution. The assay involves the technologies of target capture, transcription-mediated amplification (TMA), and hybridization protection assay (HPA). Assay test results are automatically interpreted by the Panther system Aptima TV assay software. A test result may be negative, positive, or invalid as determined by total RLU in the detection step. The current Aptima TV assay is similar to the assay cleared earlier (K122062) for use on the Panther System. There are no changes to the Aptima TV assay reagents and accessories. The Aptima Urine Specimen Collection Kit is required for the collection of male or female urine specimens. The Aptima Multitest Swab Specimen Collection Kit is intended to be used for collection and transport of clinician and patient collected vaginal swabs.

# B Principle of Operation:

The Aptima TV assay utilizes target capture, transcription-mediated amplification (TMA), and hybridization protection assay (HPA). The TMA reaction amplifies a specific region of the small ribosomal subunit from TV via DNA and RNA intermediates and generates RNA amplicon molecules. Detection of the rRNA amplification product sequences is achieved using nucleic acid based HPA. A labeled DNA probe combines with amplicon to form stable RNA: DNA hybrids. During the detection step, light emitted from the labeled RNA: DNA hybrids is measured as photon signals in a luminometer and are reported as Relative Light Units (RLU). Please refer to the decision summary of K122062 for detailed description.

# C Instrument Description Information:

1. Instrument Name: Panther System

2. Specimen Identification: By handheld barcode reader and manual entry.

3. Specimen Sampling and Handling: Fully automated

4. Calibration: The Aptima TV assay requires no calibration. The PANTHER System undergoes Preventive Maintenance every 12 months, which includes luminometer calibration.

5. Quality Controls: The Aptima Trichomonas vaginalis Controls Kit includes 5 vials each of Positive and Negative Controls which are ready to use.

# V Substantial Equivalence Information:

A Predicate Device Name(s): Aptima Trichomonas vaginalis assay (Panther System)   
B Predicate 510(k) Number(s): K122062

# C Comparison with Predicate(s):

<table><tr><td colspan="1" rowspan="1">Device &amp; PredicateDevice(s):</td><td colspan="1" rowspan="1">K122062</td><td colspan="1" rowspan="1">K231316</td></tr><tr><td colspan="1" rowspan="1">Device Trade Name</td><td colspan="1" rowspan="1">Aptima Trichomonasvaginalis Assay(Panther System)</td><td colspan="1" rowspan="1">Aptima Trichomonasvaginalis Assay(Panther System)</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristic Similarities</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Intended Use/IndicationsFor Use</td><td colspan="1" rowspan="1">The AptimaTrichomonas vaginalisAssay is an in vitroqualitative nucleic acidamplification test(NAAT) for thedetection of ribosomalRNA (rRNA) fromTrichomonas vaginalisto aid in the diagnosis oftrichomoniasis using thePanther system.The assay may be used totest the followingspecimens fromsymptomatic orasymptomatic women:clinician-collectedendocervical swabs,clinician-collectedvaginal swabs, andspecimens collected inPreservCyt Solution.</td><td colspan="1" rowspan="1">The Aptima Trichomonasvaginalis (TV) assay is anin vitro qualitativenucleic acid amplificationtest (NAAT) for thedetection of ribosomalRNA (rRNA) fromTrichomonas vaginalis toaid in the diagnosis oftrichomoniasis using thePanther System.The assay may be usedto test the followingspecimens fromsymptomatic orasymptomaticindividuals: clinician-collected endocervicalswabs, clinician-collected and patient-collected vaginal swabs(in a clinical setting),female and male urine,and specimenscollected in PreservCytSolution.</td></tr><tr><td colspan="1" rowspan="1">Assay principle</td><td colspan="1" rowspan="1">Target Capture (TC),Transcription-Mediated Amplification(TMA), HybridizationProtection Assay (HPA)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Instrumentation</td><td colspan="1" rowspan="1">PANTHER Systemautomated analyzer</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Analyte</td><td colspan="1" rowspan="1">Trichomonas vaginalisrRNA</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Amplification technology</td><td colspan="1" rowspan="1">Technology of target</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">capture, transcription-mediated amplification(TMA), and hybridizationprotection assay (HPA) tostreamline specimenprocessing, amplify targetrRNA and detectamplicon.</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Test interpretation</td><td colspan="1" rowspan="1">Automated testinterpretation</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Controls</td><td colspan="1" rowspan="1">Assay contains aninternal control for PCRfunction.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Organism detected</td><td colspan="1" rowspan="1">Trichomonas vaginalis</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristic Differences</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Specimen type</td><td colspan="1" rowspan="1">Female specimens:Vaginal swab(Clinician collected)Endocervical swabGynecologicalspecimens inPreservCyt solution</td><td colspan="1" rowspan="1">Female specimens:Vaginal swab(Clinician collected)Vaginal swab(Patient collected inclinical settings)Endocervical swabGynecological specimensinPreservCytsolution•  UrineMale Specimens:• Urine</td></tr></table>

# VI Standards/Guidance Documents Referenced:

Class II Special Controls Guideline for Industry and Food and Drug Administration Staff - Nucleic Acid Amplification Assays for the Detection of Trichomonas vaginalis

VII Performance Characteristics (if/when applicable):

# A Analytical Performance:

1. Precision/Reproducibility:

Reproducibility of the Aptima TV assay on the Panther system was previously evaluated using samples prepared in specimen transport medium (STM) and in PreservCyt Solution, reviewed under K122062.

For this submission, Aptima TV assay reproducibility on the Panther system was evaluated by testing panel members created using unique pools of negative urine specimens with Urine Transport Medium (UTM) spiked with varying concentrations of a stock solution of lysed TV organisms diluted in UTM. Final TV concentrations ranged from $0 . 0 0 3 \mathrm { ~ T V / m L }$ to $1 \ \mathrm { T V / m L }$ . The study was conducted at two external US laboratories and at Hologic, using two lots of assay reagents and a total of six operators (two at each site), testing each sample in three replicates. At each site, testing was performed over at least 6 days. The summary of reproducibility results is presented in Table 1 below.

Table 1: Aptima TV Assay Reproducibility Study   

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>ConcTV/mL</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Agreed</td><td rowspan=2 colspan=1>Agrmt(%)</td><td rowspan=2 colspan=1>MeanRLU</td><td rowspan=1 colspan=2>BetweenSites</td><td rowspan=1 colspan=2>BetweenOperators</td><td rowspan=1 colspan=2>BetweenLots</td><td rowspan=1 colspan=2>BetweenRuns</td><td rowspan=1 colspan=2>WithinRuns</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>108</td><td rowspan=1 colspan=1>108</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>24.6</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>28.3</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>72.3</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>81.4</td></tr><tr><td rowspan=1 colspan=1>HNeg</td><td rowspan=1 colspan=1>0.002</td><td rowspan=1 colspan=1>107</td><td rowspan=1 colspan=1>107</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>33.1</td><td rowspan=1 colspan=1>15.9</td><td rowspan=1 colspan=1>48.1</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>14.8</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>7.1</td><td rowspan=1 colspan=1>21.6</td><td rowspan=1 colspan=1>9.3</td><td rowspan=1 colspan=1>28.0</td><td rowspan=1 colspan=1>20.3</td><td rowspan=1 colspan=1>61.5</td></tr><tr><td rowspan=1 colspan=1>MPos</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>108</td><td rowspan=1 colspan=1>108</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>621.9</td><td rowspan=1 colspan=1>27.2</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>33.5</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>37.3</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>100.6</td><td rowspan=1 colspan=1>16.2</td><td rowspan=1 colspan=1>69.4</td><td rowspan=1 colspan=1>11.2</td><td rowspan=1 colspan=1>134.9</td><td rowspan=1 colspan=1>21.7</td></tr><tr><td rowspan=1 colspan=1>HPos</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>108</td><td rowspan=1 colspan=1>108</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>1208.3</td><td rowspan=1 colspan=1>28.8</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>140.4</td><td rowspan=1 colspan=1>11.6</td><td rowspan=1 colspan=1>41.5</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>149.2</td><td rowspan=1 colspan=1>12.3</td></tr></table>

Agrmt=Agreement with expected result, $\scriptstyle \mathrm { H N e g = H i g h }$ negative, HPos High positive, MPo $\vDash$ Moderate positive, Neg=Negative, Conc Concentration units, $\mathrm { T V / m L = }$ trichomonads/mL

2. Linearity:

Aptima TV assay is a qualitative assay, therefore a linearity study is not applicable.

3. Analytical Specificity/Interference:

# Analytical Specificity-Cross Reactivity and Microbial Interference

Analytical specificity of the Aptima TV assay was evaluated for cross-reactivity by testing various microorganisms, including common flora of the genitourinary tract, opportunistic organisms, and closely related organisms. Testing was conducted in urine in UTM with 25 replicates of each panel comprising of three different microorganisms per panel. The list of organisms and the concentrations tested are provided in Table 2. The Aptima TV Assay was also evaluated for microbial interference by testing the same organisms (Table 2) in urine in STM spiked with TV lysate to a final concentration of 0.01 TV/mL This microorganism is found in the gastrointestinal tract and not likely to be found in cervical, urine, or vaginal samples. Please refer to K122062 for the cross-reactivity/microbial interference studies conducted for previously claimed matrices in support of Aptima TV assay.

Table 2: Microorganisms Tested in the Aptima TV Assay with Urine   

<table><tr><td colspan="1" rowspan="1">Microorganism</td><td colspan="1" rowspan="1">Concentration</td><td colspan="1" rowspan="1">Microorganism</td><td colspan="1" rowspan="1">Concentration</td></tr><tr><td colspan="1" rowspan="1">Acinetobacter Iwoffi</td><td colspan="1" rowspan="1">1x106 CFU/mL</td><td colspan="1" rowspan="1">HPV 16</td><td colspan="1" rowspan="1">2.5x106 copies/mL</td></tr><tr><td colspan="1" rowspan="1">Actinomyces israelii</td><td colspan="1" rowspan="1">1x106 CFU/mL</td><td colspan="1" rowspan="1">HPV 6</td><td colspan="1" rowspan="1">2.5x106 copies/mL</td></tr><tr><td colspan="1" rowspan="1">Atopobium vaginae</td><td colspan="1" rowspan="1">1x106 CFU/mL</td><td colspan="1" rowspan="1">Klebsiella pneumoniae</td><td colspan="1" rowspan="1">1x106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Bacteroides fragilis</td><td colspan="1" rowspan="1">1x106 CFU/mL</td><td colspan="1" rowspan="1">Lactobacillus acidophilus</td><td colspan="1" rowspan="1">1x106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Bifidobacterium adolescentis</td><td colspan="1" rowspan="1">1x106 CFU/mL</td><td colspan="1" rowspan="1">Lactobacillus crispatus</td><td colspan="1" rowspan="1">1x106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Campylobacter jejuni</td><td colspan="1" rowspan="1">1x106 CFU/mL</td><td colspan="1" rowspan="1">Listeria monocytogenes</td><td colspan="1" rowspan="1">1x106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Candida albicans</td><td colspan="1" rowspan="1">1x106 CFU/mL</td><td colspan="1" rowspan="1">Mobiluncus curtisii</td><td colspan="1" rowspan="1">1x106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Chlamydia trachomatis</td><td colspan="1" rowspan="1">1x106 IFU/mL</td><td colspan="1" rowspan="1">Mycoplasma genitalium</td><td colspan="1" rowspan="1">2.5 x106 copies/mL</td></tr><tr><td colspan="1" rowspan="1">Clostridium difficile</td><td colspan="1" rowspan="1">1x106 CFU/mL</td><td colspan="1" rowspan="1">Mycoplasma hominis</td><td colspan="1" rowspan="1">1x106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Corynebacterium genitalium</td><td colspan="1" rowspan="1">1x106 CFU/mL</td><td colspan="1" rowspan="1">Neisseria gonorrhoeae</td><td colspan="1" rowspan="1">1x106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Cryptococcus neoformans</td><td colspan="1" rowspan="1">1x106 CFU/mL</td><td colspan="1" rowspan="1">Pentatrichomonas hominis</td><td colspan="1" rowspan="1">1x106 cells/mL</td></tr><tr><td colspan="1" rowspan="1">Cytomegalovirus</td><td colspan="1" rowspan="1">2x105 TCID50/mL</td><td colspan="1" rowspan="1">Peptostreptococcus magnus</td><td colspan="1" rowspan="1">1x106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Dientamoeba fragilis*</td><td colspan="1" rowspan="1">1x106 CFU/mL</td><td colspan="1" rowspan="1">Prevotella bivia</td><td colspan="1" rowspan="1">1x106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Enterobacter cloacae</td><td colspan="1" rowspan="1">1x106 CFU/mL</td><td colspan="1" rowspan="1">Propionibacterium acnes</td><td colspan="1" rowspan="1">1x106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Enterococcus faecalis</td><td colspan="1" rowspan="1">1x106 CFU/mL</td><td colspan="1" rowspan="1">Proteus vulgaris</td><td colspan="1" rowspan="1">1x106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Escherichia coli</td><td colspan="1" rowspan="1">1x106 CFU/mL</td><td colspan="1" rowspan="1">Pseudomonas aeruginosa</td><td colspan="1" rowspan="1">1x106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Gardnerella vaginalis</td><td colspan="1" rowspan="1">1x106 CFU/mL</td><td colspan="1" rowspan="1">Staphylococcus aureus</td><td colspan="1" rowspan="1">1x106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Haemophilus ducreyi</td><td colspan="1" rowspan="1">1x106 CFU/mL</td><td colspan="1" rowspan="1">Staphylococcus epidermidis</td><td colspan="1" rowspan="1">1x106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Herpes simplex virus I</td><td colspan="1" rowspan="1">2x105 TCID50/mL</td><td colspan="1" rowspan="1">Streptococcus agalactiae</td><td colspan="1" rowspan="1">1x106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Herpes simplex virus II</td><td colspan="1" rowspan="1">2x105 TCID50/mL</td><td colspan="1" rowspan="1">Trichomonas tenax</td><td colspan="1" rowspan="1">1x106 cells/mL</td></tr><tr><td colspan="1" rowspan="1">HIV-1</td><td colspan="1" rowspan="1">2.5x106 copies/mL</td><td colspan="1" rowspan="1">Ureaplasma urealyticum</td><td colspan="1" rowspan="1">1x106 CFU/mL</td></tr></table>

# Interfering Substances

The analytical performance of the Aptima TV assay was evaluated in the presence of a panel of potentially interfering substances that may be found in urine samples. Each potential interferent was organized in panels comprising of representatives of personal lubricant, personal deodorant, antifungal agents, and representatives of spermicide and intravaginal hormone (Table 3). Additionally, porcine mucin (used to simulate the major biological component of cervical mucus), seminal fluid from 25 subjects, whole blood, glacial acetic acid and commercially prepared Kova-Trol I were used to evaluate the interference from endogenous substances (commercially available Kova-Trol I is a ready-to-use liquid control at clinically high concentrations). Each potential interferent was spiked into urine/ UTM diluted samples, containing TV organisms at the concentration of $0 . 0 1 \mathrm { ~ T V / m L }$ , to a final indicated concentration (vol/vol, V/V or wt/vol, W/V), as shown in Table 3. Additionally, each interferent was spiked into urine/ UTM with no TV present. Tests for all interference substances, with the exception of glacial acetic acid, mucin and astroglide lubricant, generated expected results, demonstrating that the substances listed at the concentrations shown in Table 3, do not interfere with the Aptima TV assay. Glacial acetic acid, mucin and astroglide lubricant interfered with performance of TV detection at concentration of $0 . 0 1 \mathrm { ~ T V / m L }$ causing false negative results. However. these substances did not interfere with TV detection when tested at higher concentrations, i.e., of $0 . 3 \mathrm { \ T V / m L }$ when tested in the presence of astroglide lubricant, and $1 \ \mathrm { T V / m L }$ when tested in the presence of mucin and glacial acetic acid. Please refer to K122062 for the interference studies conducted for previously claimed matrices in support of Aptima TV assay.

Table 3: Substances evaluated in the Interference Study with Urine   

<table><tr><td rowspan=1 colspan=1>Product Category</td><td rowspan=1 colspan=1>Product Brand or Type</td><td rowspan=1 colspan=1>Concentration</td></tr><tr><td rowspan=1 colspan=1>Lubricant (V/V)</td><td rowspan=1 colspan=1>KY Warming Liquid, KY S ensitiveTouch Target Lubricant Liquid,Astroglide KY Sensitive Jelly *</td><td rowspan=1 colspan=1>1%</td></tr><tr><td rowspan=1 colspan=1>Spermicide (W/V)</td><td rowspan=1 colspan=1>Gynol II Jelly Max Strength;Conceptrol VCF VaginalContraceptive Film Encare Inserts</td><td rowspan=1 colspan=1>1%</td></tr><tr><td rowspan=1 colspan=1>Anti-fungal (W/V)</td><td rowspan=1 colspan=1>Monistat 3 Combo, CVS Clotrimazole3, Target Vagicaine Cream, VagisilMaximum Strength, TarqetMiconazole 7</td><td rowspan=1 colspan=1>1%</td></tr><tr><td rowspan=1 colspan=1>Deodorant Spray/Powder (W/V)</td><td rowspan=1 colspan=1>Summer&#x27;s Eve Powder, Vagisil PowderSummer&#x27;s Eve, Spray New FreshnessSpray, FDS Spray</td><td rowspan=1 colspan=1>1%</td></tr><tr><td rowspan=1 colspan=1>lntravaginal Hormone (W/V)</td><td rowspan=1 colspan=1>Estrace Vaginal Cream (estradiol),CrinoneGel (progesterone)Endometrin tablets (progesterone)Vagifem tablets (estradiol)</td><td rowspan=1 colspan=1>1%</td></tr><tr><td rowspan=1 colspan=1>Seminal Fluid (V/V)</td><td rowspan=1 colspan=1>Samples from 25 subjects</td><td rowspan=1 colspan=1>10%</td></tr><tr><td rowspan=1 colspan=1>Mucus (W/V) *</td><td rowspan=1 colspan=1>Porcine Mucin</td><td rowspan=1 colspan=1>10%</td></tr><tr><td rowspan=1 colspan=1>Whole Blood (V/V)</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>100% in place ofurine</td></tr><tr><td rowspan=1 colspan=1>Glacial Acetic Acid (V/V) *</td><td rowspan=1 colspan=1>EMD Chemicals, Alfa Aesar (retest at 1TVmL)</td><td rowspan=1 colspan=1>1%</td></tr><tr><td rowspan=1 colspan=1>Urine Metabolites</td><td rowspan=1 colspan=1>KOVA-Trol I High Abnormal withUrobilinogen</td><td rowspan=1 colspan=1>100% in place ofurine</td></tr></table>

\* These substances interfered with performance of Aptima TV assay at the indicated tested concentrations and resulted in false positives in urine -UTM samples containing 0.01 TV/mL.

# 4. Assay Reportable Range:

Aptima TV assay is a qualitative assay; therefore, a measuring range study is not applicable.

5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):

The stability of urine specimens was evaluated in an analytical study which used individual negative female urine specimens spiked with freshly cultured TV and replicates tested at baseline and after storage. The study results demonstrated urine samples are stable when stored neat for 24 hours at $3 0 \mathrm { { ^ \circ C } }$ and when stored in UTM for 30 days at $3 0 \mathrm { { } ^ { \circ } C }$ or up to 24 months at $- 2 0 ^ { \circ } \mathrm { C }$ .

# 6. Detection Limit:

The limit of detection (LoD) for the Aptima TV assay was determined by testing two quantified $\mathrm { ( T V / m L ) }$ strains of TV spiked into negative pools of female urine matrix. One batch of each cultured TV strain, ATCC #30236 (metronidazole-sensitive strain) and ATCC #50138 (metronidazole-resistant strain) were used in this study. Results demonstrated greater than $9 5 \%$ positivity for both strains of TV at 0.01 TV/mL in urine specimen matrix. Please refer to K122062 for the Detection Limit studies conducted for previously claimed matrices in support of Aptima TV assay.

Please refer to K122062 for the carry-over studies conducted in support of the Aptima TV assay on the Panther instrument.

8. Accuracy (Instrument): Not applicable.

9. Carry-Over:

Please refer to K122062 for the carry-over studies conducted in support of the Aptima TV assay.

# B Comparison Studies:

1. Method Comparison with Predicate Device: See Clinical Studies section below.

2. Matrix Comparison: Not applicable.

# C Clinical Studies:

# Clinical Performance

The clinical performance of the Aptima TV assay on the Panther system with urine (male and female) and self-collected vaginal specimens, was evaluated in a prospective, multicenter clinical study.

Symptomatic and asymptomatic men and women were enrolled at 11 geographically and ethnically diverse US clinical sites, including obstetrics and gynecology, family planning, and STI clinics.

Up to five specimens were collected from each female subject (four patient-collected vaginal swabs, one first-catch urine), and one first catch urine specimen was collected from each male subject. All specimens were collected by the subject at the clinical sites.

Of the specimens collected, 5922 were processed in valid Aptima TV assay runs. Of these, 225 samples generated invalid results upon initial testing (invalid rate of $3 . 8 \%$ , $9 5 \%$ CI: $3 . 3 \% 6 \ – 4 . 3 \%$ ); after retesting, 89 samples remained invalid.

The clinical performance of the Aptima TV assay with vaginal swabs and female and male urine was evaluated testing each sample with up to three FDA-cleared NAATs for detection of TV. Specimens were categorized as “infected” (patient infected status, PIS) for vaginal swabs and male urine and as “positive” (composite comparator algorithm, CCA) for female urine if a positive result occurred in at least two of the comparator NAAT results, and as “not infected”/ “negative” if at least two of the comparator results were negative; the third (tie-breaker) NAAT was only required if the first two NAAT results were discordant. Specimens that could not be categorized as infected/positive or not infected/negative due to missing results from the comparator assays were excluded from the performance analyses.

A total of 5502 specimens from 3820 evaluable subjects were included in the analyses comparing Aptima TV assay results to the PIS or CCA interpretation: 1785 patient- collected vaginal swabs, 1782 female urine specimens, and 1935 male urine specimens.

Performance characteristics of the Aptima TV assay, are shown below in Table 4 and 5.

Table 4: Clinical Performance of the Aptima TV assay Compared to PIS, by Symptom Status   

<table><tr><td rowspan=1 colspan=1>SpecimenType</td><td rowspan=1 colspan=1>SymptomStatus</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>TP</td><td rowspan=1 colspan=1>FP</td><td rowspan=1 colspan=1>TN</td><td rowspan=1 colspan=1>FN</td><td rowspan=1 colspan=1>Sensitivity% (95% CI)</td><td rowspan=1 colspan=1>Specificity% (95% CI)</td></tr><tr><td rowspan=3 colspan=1>PVS</td><td rowspan=1 colspan=1>Asymptomatic</td><td rowspan=1 colspan=1>932</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>868</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>96.7 (88.8-99.1)</td><td rowspan=1 colspan=1>99.7 (99.0-99.9)</td></tr><tr><td rowspan=1 colspan=1>Symptomatic</td><td rowspan=1 colspan=1>853</td><td rowspan=1 colspan=1>99</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>748</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100 (96.3-100)</td><td rowspan=1 colspan=1>99.2 (98.3-99.6)</td></tr><tr><td rowspan=1 colspan=1>All</td><td rowspan=1 colspan=1>1785</td><td rowspan=1 colspan=1>158</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>1616</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>98.8 (95.6-99.7)</td><td rowspan=1 colspan=1>99.4 (99.0-99.7)</td></tr><tr><td rowspan=3 colspan=1>MU</td><td rowspan=1 colspan=1>Asymptomatic</td><td rowspan=1 colspan=1>1125</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1103</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100 (84.5-100)</td><td rowspan=1 colspan=1>99.9 (99.5-100)</td></tr><tr><td rowspan=1 colspan=1>Symptomatic</td><td rowspan=1 colspan=1>810</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>787</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100 (84.5-100)</td><td rowspan=1 colspan=1>99.7 (99.1-99.9)</td></tr><tr><td rowspan=1 colspan=1>All</td><td rowspan=1 colspan=1>1935</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1890</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100 (91.6-100)</td><td rowspan=1 colspan=1>99.8 (99.5-99.9)</td></tr></table>

$\mathrm { P V S } =$ patient-collected vaginal swab, $\mathbf { M U } =$ male urine, $\mathrm { T P } =$ true positive, $\mathrm { F P = }$ false positive, $\mathrm { T N } =$ true negative, $\mathrm { F N = }$ false negative.

The TV specimen specific positive and negative percent agreements (PPA and NPA) between the Aptima TV assay and up to three FDA cleared NAATs with female urine specimen are shown below in Table 5.

Table 5: TV Specimen Specific Agreement for Female Urine, by Symptom Status   

<table><tr><td rowspan=1 colspan=1>SpecimenType</td><td rowspan=1 colspan=1>SymptomStatus</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>CCA+ATV+</td><td rowspan=1 colspan=1>CCA-ATV+</td><td rowspan=1 colspan=1>CCA-ATV-</td><td rowspan=1 colspan=1>CCA+ATV-</td><td rowspan=1 colspan=1>PPA% (95% CI)</td><td rowspan=1 colspan=1>NPA% (95% CI)</td></tr><tr><td rowspan=3 colspan=1>FU</td><td rowspan=1 colspan=1>Asymptomatic</td><td rowspan=1 colspan=1>949</td><td rowspan=1 colspan=1>64</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>885</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100 (94.3-100)</td><td rowspan=1 colspan=1>100 (99.6-100)</td></tr><tr><td rowspan=1 colspan=1>Symptomatic</td><td rowspan=1 colspan=1>833</td><td rowspan=1 colspan=1>94</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>739</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100 (96.1-100)</td><td rowspan=1 colspan=1>100 (99.5-100)</td></tr><tr><td rowspan=1 colspan=1>All</td><td rowspan=1 colspan=1>1782</td><td rowspan=1 colspan=1>158</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1624</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100 (97.6-100)</td><td rowspan=1 colspan=1>100 (99.8-100)</td></tr></table>

$\mathrm { F U } =$ female urine, TP $=$ true positive, $\mathrm { F P = }$ false positive, TN $=$ true negative, $\mathrm { F N = }$ false negative, $\mathrm { P P A } =$ positive percent agreement, $\mathrm { \Delta N P A = }$ negative percent agreement. $\mathbf { A } \mathrm { T V } =$ Aptima TV assay

The sensitivity of the Aptima TV assay on the Panther system in female urine specimens was also assessed compared to three comparator NAAT results obtained by testing patient-collected vaginal swabs (PIS). The data showed that the detection of TV infection in female urine specimens by the Aptima TV assay is up to $2 . 4 \%$ lower than when testing vaginal swab specimens when compared to PIS.

# D Clinical Cut-Off:

Not Applicable.

# E Expected Values/Reference Range:

The positivity of T. vaginalis, as determined by the Aptima TV assay, during the clinical study is shown in Table 6 below.

# Table 6: Positivity of T. vaginalis as Determined by the Aptima TV assay, by Sample Type, stratified by Clinical Sites

<table><tr><td rowspan=1 colspan=1>Site</td><td rowspan=1 colspan=1>PVS</td><td rowspan=1 colspan=1>FU</td><td rowspan=1 colspan=1>MU</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0 (0/16)</td><td rowspan=1 colspan=1>0 (0/16)</td><td rowspan=1 colspan=1>0 (0/180)</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>11.1 (36/325)</td><td rowspan=1 colspan=1>10.4 (38/364)</td><td rowspan=1 colspan=1>4.4 (16/364)</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>8.5 (6/71)</td><td rowspan=1 colspan=1>9.5 (7/74)</td><td rowspan=1 colspan=1>1.7 (1/60)</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>NC (0/0)</td><td rowspan=1 colspan=1>NC (0/0)</td><td rowspan=1 colspan=1>0 (0/13)</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>8.8 (15/170)</td><td rowspan=1 colspan=1>8.8 (15/171)</td><td rowspan=1 colspan=1>2.9 (12/407)</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>5.8 (24/416)</td><td rowspan=1 colspan=1>5.8 (24/413)</td><td rowspan=1 colspan=1>0.7 (2/304)</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>6.1 (11/179)</td><td rowspan=1 colspan=1>5.3 (10/187)</td><td rowspan=1 colspan=1>1.3 (3/225)</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0 (0/38)</td><td rowspan=1 colspan=1>0 (0/39)</td><td rowspan=1 colspan=1>0 (0/32)</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>10.8 (32/297)</td><td rowspan=1 colspan=1>9.8 (25/255)</td><td rowspan=1 colspan=1>2.4 (5/210)</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>20.2 (37/183)</td><td rowspan=1 colspan=1>19.8 (36/182)</td><td rowspan=1 colspan=1>6.7 (6/89)</td></tr><tr><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>6.7 (6/90)</td><td rowspan=1 colspan=1>3.7 (3/81)</td><td rowspan=1 colspan=1>0 (0/51)</td></tr><tr><td rowspan=1 colspan=1>ALL</td><td rowspan=1 colspan=1>9.4 (167/1785)</td><td rowspan=1 colspan=1>8.9 (158/1782)</td><td rowspan=1 colspan=1>2.3 (45/1935)</td></tr></table>

$\mathrm { P V S } =$ patient-collected vaginal swab, FU $=$ female urine, $\mathbf { M U } =$ male urine, $\mathrm { N C } =$ not calculable.

# F Other Supportive Instrument Performance Characteristics Data: Not applicable

# VIII Proposed Labeling:

The labeling is acceptable and supports the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.